Share
Respiratory Virus Infection Drugs Market: By Drug Type (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Cough Suppressants, Nasal Decongestants), By Infection Type (Respiratory Syncytial Virus [RSV] Infection, Influenza & Parainfluenza Virus Infection, Adenovirus & Rhinovirus Infection), By Route of Administration (Oral, Parenteral), By Mode of Purchase (Prescription-Based Drugs, Over-the-Counter Drugs), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics), And Region - Global Analysis of Market Size, Share & Trends For 2021-2022 And Forecasts To 2032
Respiratory Virus Infection Drugs are medicines that treat viral infections. Antiviral medications are a specific class of medications that are used to treat viral infections. They work by eliminating or stopping the spread of viruses. Antiviral drugs used to treat the flu include oseltamivir (Tamiflu) and zanamivir (Relenza). One of these medicines may be prescribed to the patients. Acyclovir (Zovirax), famciclovir (Famvir), and valacyclovir (Valtrex) are other antiviral medications that are effective against herpesvirus, including herpes zoster and herpes genitalis. Since these medications are only available by prescription, avoid buying them from online sources. Respiratory viral infections may vary from person to person, hence doctor’s prescribed medicines are recommended.
Respiratory Virus Infection Drugs Market to surpass USD 88.9 billion by 2032 from USD 41.46 billion in 2021 at a CAGR of 7.2% in the coming years, i.e., 2022-32. Heavy investments made by the key players in the market for the creation of cutting-edge medicines are fueling the global Respiratory Virus Infection Drugs Market. Moreover, the market participants will benefit greatly from the growing acceptance of combination therapy to raise the success rate of respiratory treatments. The global market is driven by these key elements.
Get More Information - Download Free Sample
Respiratory Virus Infection Drugs Market is categorized on the basis of Drug Type into Antibiotics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cough Suppressants, Nasal Decongestants, and Others. Over the estimated period, the antibiotics sector is anticipated to dominate the market. A class of medicines known as macrolides is observed as a promising alternative for treating viral respiratory infections. This will probably grow the segment over the coming years.
Respiratory Virus Infection Drugs Market is categorized on the basis of Infection Type into Respiratory Syncytial Virus (RSV) Infection, Influenza Virus Infection, Parainfluenza Virus Infection, Adenovirus Infection, Rhinovirus Infection, and Others. In the upcoming years, the Respiratory Syncytial Virus (RSV) Infection segment share is anticipated to grow significantly. Adults who have congestive heart failure, COPD, or asthma are more likely to get a respiratory syncytial virus infection. As a result, the category is expected to grow as more patients are developing these risk factors.
Get More Information - Download Free Sample
The widespread application of machine learning and artificial intelligence in drug discovery is anticipated to positively impact the Respiratory Virus Infection Drugs Market. It is anticipated that widespread usage of combination therapy will increase the rate of success in treating respiratory virus infections with antiviral medications. As a result, the size of the Respiratory Virus Infection Drugs Market will increase in the years to come. In addition, efficient drug delivery using nanotechnology is anticipated to open up new potential opportunities for the market for pharmaceuticals treating respiratory viral infections in the near future. Moreover, the growth of the Respiratory Virus Infection Drugs Market will be boosted by an increase in healthcare spending and a surge in vaccination efforts.
Owing to the increasing number of patients and the growth of the Respiratory Virus Infection Drugs Market is anticipated to increase. Rising rates of respiratory infections, technological breakthroughs, such as the use of nanotechnology in virology and the potential for antiviral therapies, and rising demand for high-quality healthcare are the primary market drivers. Increases in patient volume, health insurance demand, middle-class income, and public awareness of high-quality healthcare are all contributing to the market's growth.
Patents prevent rival producers from creating medicines that are only produced by the patent holders. The pharmaceutical sector is significantly impacted when a patent-branded drugs expire. It hinders sales of branded medications and might have an impact on a company's market share. The global Respiratory Virus Infection Drugs Market is hence projected to limit the market growth.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Respiratory Virus Infection Drugs Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. In 2020, North America held the largest market share for the Respiratory Virus Infection Drugs Market, followed by Europe. The region's Respiratory Virus Infection Drugs Market is expected to be driven by the presence of major players and a focus on research and development.
Impact of Covid-19 on Respiratory Virus Infection Drugs Market
The COVID-19 pandemic had a significant impact on the way Respiratory Virus Infection Drug producers, suppliers, and distributors conducted business. It is anticipated that after, as compared to the pre-COVID-19 stage, the fall in Respiratory Virus Infection Drugs export shipments and slow domestic demand negatively affected and somewhat reduced the demand for these drugs. For the top businesses in this sector, the pandemic's impact was noticeable in the first half of 2020.
REPORT ATTRIBUTE |
DETAILS |
|
Market Size Value in 2021 |
USD 41.46 billion |
|
Revenue Forecast in 2032 |
USD 88.9 billion |
|
Growth Rate |
CAGR of 7.2% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Quantitative Units |
Revenue in USD billion and CAGR from 2022 to 2032 |
|
Report Coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments Covered |
Drug Type, Infection Type, Route of Administration, Mode of Purchase, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
|
Key Companies Profiled |
Johnson & Johnson, Roche Holding AG, Sanofi, GlaxoSmithKline plc, AstraZeneca, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla Inc., Gilead Sciences, Teva Pharmaceutical Industries Ltd., Orion Corporation, Alnylam Pharmaceuticals, CHIESI Farmaceutici S.p.A., Bavarian Nordic, ImmunoVaccine Technologies, and Other Prominent Players. |
The Respiratory Virus Infection Drugs Market size was estimated at USD 41.46 billion in 2021 and is expected to reach USD 88.9 billion in 2032.
Respiratory Virus Infection Drugs are used to treat viral infections. Antiviral medications are a specific class of medications that are used to treat viral infections. They work in eliminating or stopping the spread of viruses.
The Antibiotics and Respiratory Syncytial Virus (RSV) Infection segments accounted for the larger share of the Respiratory Virus Infection Drugs Market.
Key players in the Respiratory Virus Infection Drugs Market are Johnson & Johnson, Roche Holding AG, Sanofi, GlaxoSmithKline plc, AstraZeneca, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla Inc., Gilead Sciences, Teva Pharmaceutical Industries Ltd., Orion Corporation, Alnylam Pharmaceuticals, CHIESI Farmaceutici S.p.A., Bavarian Nordic, ImmunoVaccine Technologies, and Other Prominent Players.
Heavy investments made by the key players of the market for the creation of cutting-edge medicines are fueling the global Respiratory Virus Infection Drugs Market.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
